ARS Pharmaceuticals reported a gross margin of 61.83% and a net margin of -190.11% for the quarter ended Jun 2026. These financial ratios cover 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||||||||
| Gross Margin | 100.00% | 94.58% | 99.00% | 86.28% | 68.29% | 74.80% | 78.09% | 72.29% | 61.83% | ||||||||||||||
| EBT Margin | -1,070.74% | -1,367.24% | -3,507.94% | -95,260.00% | -208,510.00% | -3,072.20% | -1,028.24% | 54.37% | -468.14% | -303.70% | -163.54% | -147.16% | -276.91% | -190.11% | |||||||||
| EBIT Margin | -1,070.74% | -1,367.24% | -3,507.94% | -93,565.00% | -206,030.00% | -3,068.00% | -1,051.64% | 54.51% | -466.29% | -302.95% | -163.66% | -147.63% | -265.18% | -182.62% | |||||||||
| EBITDA Margin | -1,070.74% | -1,367.24% | -3,507.94% | -93,565.00% | -206,030.00% | -3,068.00% | -1,051.64% | 54.51% | -466.29% | -302.95% | -163.66% | -147.63% | -265.18% | -182.62% | |||||||||
| Operating Margin | -1,070.74% | -1,367.24% | -3,507.94% | -93,565.00% | -206,030.00% | -3,068.00% | -1,051.64% | 54.51% | -466.29% | -302.95% | -163.66% | -147.63% | -265.18% | -182.62% | |||||||||
| Net Margin | -1,070.74% | -1,367.24% | -3,507.94% | -95,260.00% | -208,510.00% | -3,072.20% | -1,028.24% | 54.37% | -468.14% | -303.70% | -163.54% | -147.16% | -276.91% | -190.11% | |||||||||
| FCF Margin | -1,047.66% | -1,507.76% | -3,022.22% | -63,110.00% | -166,990.00% | -1,463.40% | -706.33% | 48.17% | -512.14% | -252.23% | -145.36% | -154.82% | -198.17% | -181.02% | |||||||||
| Efficiency | |||||||||||||||||||||||
| Inventory AverageInventory Avg. | 2.96M | 6.24M | 8.00M | 8.26M | 8.08M | 8.59M | 10.25M | ||||||||||||||||
| Assets AverageAssets Avg. | 359.77M | 207.00M | 186.96M | 303.23M | 282.53M | 276.25M | 276.31M | 264.97M | 253.65M | 240.87M | 230.39M | 224.77M | 219.78M | 284.38M | 339.24M | 320.39M | 343.14M | 350.23M | 307.61M | 268.53M | |||
| Invested CapitalInvested Cap. | 332.13M | -22.86M | 272.89M | 230.76M | 326.18M | 298.36M | 264.28M | 243.88M | 210.63M | 157.83M | 109.19M | ||||||||||||
| Asset Utilization RatioAsset Util. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.31 | 0.29 | 0.35 | 0.42 | 0.24 | 0.32 | 0.44 | ||||||||
| Leverage & Solvency | |||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | -24.64 | -24.79 | |||||||||||||||||||||
| Debt Ratio | 0.14 | 0.20 | 0.21 | 0.23 | 0.26 | 0.29 | 0.34 | 0.39 | |||||||||||||||
| Times Interest Earned | -24.64 | -24.79 | |||||||||||||||||||||
| Valuation | |||||||||||||||||||||||
| Price to EarningsP/E | -22.67 | -32.27 | -30.63 | -20.16 | -52.75 | -73.85 | -53.70 | -66.25 | 21.95 | -33.07 | -36.08 | -18.69 | -27.99 | -12.70 | -12.45 | ||||||||
| Price to SalesP/S | 0.03M | 0.06M | 0.00M | 681.16 | 11.94 | 154.83 | 109.58 | 30.56 | 41.18 | 35.16 | 23.66 | ||||||||||||
| Price to BookP/B | 1.25 | 2.35 | 2.57 | 1.53 | 2.29 | 4.41 | 3.83 | 7.01 | 4.02 | 5.39 | 8.96 | 6.73 | 10.12 | 13.01 | 63.66 | ||||||||
| Enterprise Value | 66.44M | 350.31M | 386.46M | 120.21M | 299.99M | 763.35M | 606.21M | 1,204.01M | 719.39M | 958.75M | 1,482.14M | 705.18M | 911.75M | 596.41M | 652.65M | ||||||||
| EV to EBIT | -4.30 | -18.72 | -18.76 | -6.69 | -29.34 | -57.86 | -39.52 | -55.36 | 15.24 | -25.79 | -31.13 | -13.26 | -21.99 | -9.92 | -10.62 | ||||||||
| EV to EBITDA | -4.30 | -18.72 | -18.76 | -6.69 | -29.34 | -57.86 | -39.52 | -55.36 | 15.24 | -25.79 | -31.13 | -13.26 | -21.99 | -9.92 | -10.62 | ||||||||
| Market Capitalization | 340.83M | 614.86M | 638.66M | 362.11M | 528.35M | 986.99M | 824.96M | 1,408.64M | 1,033.42M | 1,234.47M | 1,722.27M | 993.38M | 1,156.74M | 797.38M | 796.50M | ||||||||
| Price to FCFP/FCF | -16.53 | -48.71 | -38.25 | -28.28 | -30.52 | -145.29 | -112.75 | -96.44 | 24.78 | -30.23 | -43.44 | -21.03 | -26.60 | -17.74 | -13.07 | ||||||||
| EV to FCF | -3.22 | -27.75 | -23.14 | -9.39 | -17.33 | -112.37 | -82.85 | -82.43 | 17.25 | -23.48 | -37.39 | -14.93 | -20.97 | -13.27 | -10.71 | ||||||||
| EV to CFO | -3.24 | -28.18 | -23.18 | -9.42 | -17.24 | -113.76 | -83.28 | -83.22 | 17.13 | -23.53 | -37.44 | -14.99 | -20.97 | -13.27 | -10.71 | ||||||||
| Return Ratios | |||||||||||||||||||||||
| Return on Sales [ROS]ROS | -1,070.74% | -1,367.24% | -3,507.94% | -2,698.78% | -93,565.00% | -206,030.00% | -242,456.67% | -225,066.67% | -619,990.00% | -3,068.00% | -1,051.64% | 54.51% | -466.29% | -302.95% | -163.66% | -147.63% | -265.18% | -182.62% | |||||
| Return on Capital Employed [ROCE]ROCE | -22.99% | -9.78% | -4.45% | 3.59% | 9.53% | -13.11% | -17.69% | -24.08% | -30.00% | -28.31% | -27.35% | -26.02% | -29.78% | -1.18% | -8.69% | -21.59% | -31.06% | -57.69% | -78.46% | -104.14% | |||
| Return on Assets [ROA]ROA | -22.02% | -9.40% | -4.10% | 3.46% | 9.41% | -12.71% | -17.03% | -23.24% | -28.74% | -28.18% | -26.99% | -25.23% | -27.30% | -1.02% | -7.92% | -18.49% | -26.56% | -51.26% | -66.65% | -82.40% |